UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Synthetic studies on the indane SHIP1 agonist AQX-1125

Organic & biomolecular chemistry, 2022-05, Vol.2 (19), p.416-42

2022

Link zum Volltext

Verfügbarkeit prüfen

AQX‐1125, small molecule SHIP1 activator inhibits bleomycin‐induced pulmonary fibrosis

British journal of pharmacology, 2017-09, Vol.174 (18), p.3045-3057

2017

Link zum Volltext

Verfügbarkeit prüfen

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo

British journal of pharmacology, 2013-03, Vol.168 (6), p.1506-1518

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo

British journal of pharmacology, 2013-03, Vol.168 (6), p.1519-1529

2013

Link zum Volltext

Verfügbarkeit prüfen

The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma

Clinical and experimental allergy, 2014-09, Vol.44 (9), p.1146-1153

2014

Link zum Volltext

Verfügbarkeit prüfen

SHIP1 Activator AQX-1125 Regulates Osteogenesis and Osteoclastogenesis Through PI3K/Akt and NF-κb Signaling

Frontiers in cell and developmental biology, 2022-04, Vol.10, p.826023-826023

2022

Link zum Volltext

Verfügbarkeit prüfen

P31 - Rates and routes of excretion of 14C-AQX-1125 following oral administration to rats, dogs and humans

Drug metabolism and pharmacokinetics, 2020, Vol.35 (1), p.S30-S30

2020

Link zum Volltext

Verfügbarkeit prüfen

P32 - Comparative metabolism of 14C-AQX-1125 following oral administration to rats, dogs and humans

Drug metabolism and pharmacokinetics, 2020, Vol.35 (1), p.S30-S31

2020

Link zum Volltext

Verfügbarkeit prüfen

D37 COPD: DEVELOPMENTAL THERAPEUTICS: Safety And Efficacy Of Aqx-1125 In Chronic Obstructive Pulmonary Disease (COPD) - Results Of The Phase 2 Flagship Study

American journal of respiratory and critical care medicine, 2016-01, Vol.193, p.1

2016

Link zum Volltext

Verfügbarkeit prüfen

The effects of the novel SHIP 1 activator AQX ‐1125 on allergen‐induced responses in mild‐to‐moderate asthma

Clinical and experimental allergy, 2014-09, Vol.44 (9), p.1146-1153

2014

Link zum Volltext

Verfügbarkeit prüfen

B39 COPD EXACERBATIONS: PRECIPITATING FACTORS, PREVENTION, AND OUTCOME: The Flagship Study: A 12-Week Phase Ii Study To Evaluate The Efficacy And Safety Of Aqx-1125 Following Exacerbations In Patients With Chronic Obstructive Pulmonary Disease (COPD) By Targeting The Ship1 Pathway

American journal of respiratory and critical care medicine, 2014-01, Vol.189, p.1

2014

Link zum Volltext

Verfügbarkeit prüfen

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis

British journal of pharmacology, 2013-02, Vol.168 (6), p.1506-1518

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models

British journal of pharmacology, 2013-02, Vol.168 (6), p.1519-1529

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization of AQX‐1125, a small‐molecule SHIP1 activator

British journal of pharmacology, 2013-03, Vol.168 (6), p.1519-1529

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization of AQX‐1125, a small‐molecule SHIP1 activator

British journal of pharmacology, 2013-03, Vol.168 (6), p.1506-1518

2013

Link zum Volltext

Verfügbarkeit prüfen

Serum antibody responses in horses and mice following immunization with Actinobacillus equuli outer membrane proteins and recombinant Aqx toxin

The veterinary journal (1997), 2011-11, Vol.190 (2), p.e91-e94

2011

Link zum Volltext

Verfügbarkeit prüfen

AQX-1125, a Modulator of the SHIP1/PI3K Pathway, Suppresses Chemotaxis and Inflammation

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB65-AB65

2011

Link zum Volltext

Verfügbarkeit prüfen

Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC)

Expert opinion on investigational drugs, 2016-05, Vol.25 (5), p.521-529

2016

Link zum Volltext

Verfügbarkeit prüfen

Serum antibodies in mares and foals to Actinobacillus equuli whole cells, outer membrane proteins, and Aqx toxin

Veterinary Immunology and Immunopathology, 2007-08, Vol.118 (3), p.310-316

2007

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Aqx and its operon: the hemolytic RTX determinant of Actinobacillus equuli

Veterinary microbiology, 2002-06, Vol.87 (2), p.159-174

2002

Link zum Volltext

Verfügbarkeit prüfen

Lower Urinary Tract Symptoms: What’s New in Medical Treatment?

European urology focus, 2018-01, Vol.4 (1), p.17-24

2018

Link zum Volltext

Verfügbarkeit prüfen

Exercise shoes.(Product News)(AQx Sports Aquatic Training Shoes)

Physical therapy, 2008-02, Vol.88 (2)

2008

Link zum Volltext

Verfügbarkeit prüfen

AQx Sports.(AQx Sports launches new Web site )(Brief article)

Physical therapy, 2007-11, Vol.87 (11), p.S17

2007

Link zum Volltext

Verfügbarkeit prüfen

Antibodies to aqx toxin of Actinobacillus equuli in horses and foals

Veterinary record, 2004-08, Vol.155 (8), p.231-233

2004

Link zum Volltext

Verfügbarkeit prüfen

Antibodies to Aqx toxin of Actinobacilus equuli in horses and foals

Veterinary record, 2004-08, Vol.155 (8), p.231-233

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 4.546

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.400)
Mit Volltextzugriff
(4.302)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

13 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Electronic Journals Library - Freely accessible e-journals
(1.938)
Journals@Ovid Complete
(985)
Single Journals
(908)
Oxford Journals
(702)
Oxford Journals 2020 Medicine
(676)
JSTOR Complete Journals
(640)
Ingenta
(611)
SpringerLink (Online service)
(479)
eBooks on EBSCOhost
(369)
Ebook Central Perpetual and DDA
(360)
De Gruyter journals
(351)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(333)
IngentaConnect Journals
(329)
De Gruyter eBooks
(249)
Nexis Uni
(194)
Factiva
(190)
Wiley-Blackwell Full Collection
(147)
Springer Books
(99)
Wiley Online Library Full Collection 2018
(97)
EBSCOhost Business Source Ultimate
(95)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

American Journal Of Clinical Pathology
(671)
Hermes
(244)
Philologus
(196)
Glotta
(81)
Klio
(74)
Athenaeum
(63)
Mnemosyne
(57)
The Times Educational Supplement
(55)
Balkan Studies
(49)
Rivista Di Filologia E Di Istruzione Classica
(48)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Synthetic studies on the indane SHIP1 agonist AQX-1125

AQX‐1125, small molecule SHIP1 activator inhibits bleomycin‐induced pulmonary fibrosis

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo

The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma

SHIP1 Activator AQX-1125 Regulates Osteogenesis and Osteoclastogenesis Through PI3K/Akt and NF-κb Signaling

P31 - Rates and routes of excretion of 14C-AQX-1125 following oral administration to rats, dogs and humans

P32 - Comparative metabolism of 14C-AQX-1125 following oral administration to rats, dogs and humans

D37 COPD: DEVELOPMENTAL THERAPEUTICS: Safety And Efficacy Of Aqx-1125 In Chronic Obstructive Pulmonary Disease (COPD) - Results Of The Phase 2 Flagship Study

The effects of the novel SHIP 1 activator AQX ‐1125 on allergen‐induced responses in mild‐to‐moderate asthma

B39 COPD EXACERBATIONS: PRECIPITATING FACTORS, PREVENTION, AND OUTCOME: The Flagship Study: A 12-Week Phase Ii Study To Evaluate The Efficacy And Safety Of Aqx-1125 Following Exacerbations In Patients With Chronic Obstructive Pulmonary Disease (COPD) By Targeting The Ship1 Pathway

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models

Characterization of AQX‐1125, a small‐molecule SHIP1 activator

Characterization of AQX‐1125, a small‐molecule SHIP1 activator

Serum antibody responses in horses and mice following immunization with Actinobacillus equuli outer membrane proteins and recombinant Aqx toxin

AQX-1125, a Modulator of the SHIP1/PI3K Pathway, Suppresses Chemotaxis and Inflammation

Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC)

Serum antibodies in mares and foals to Actinobacillus equuli whole cells, outer membrane proteins, and Aqx toxin

Characterization of Aqx and its operon: the hemolytic RTX determinant of Actinobacillus equuli

Lower Urinary Tract Symptoms: What’s New in Medical Treatment?

Exercise shoes.(Product News)(AQx Sports Aquatic Training Shoes)

AQx Sports.(AQx Sports launches new Web site )(Brief article)

Antibodies to aqx toxin of Actinobacillus equuli in horses and foals

Antibodies to Aqx toxin of Actinobacilus equuli in horses and foals

Suchergebnisse filtern